Radiation dose determines the degree of myeloid engraftment after nonmyeloablative stem cell transplantation  by Kahl, Christoph et al.
R
E
T
I
o
(
b
i
f
T
(
l
p
m
r
u
c
d
c
f
Biology of Blood and Marrow Transplantation 10:826-833 (2004)
 2004 American Society for Blood and Marrow Transplantation
1083-8791/04/1012-0002$30.00/0
doi:10.1016/j.bbmt.2004.09.002
8adiation Dose Determines the Degree of Myeloid
ngraftment after Nonmyeloablative Stem Cell
ransplantation
Christoph Kahl, Marco Mielcarek, Mineo Iwata, Michael A. Harkey, Barry Storer, Beverly Torok-Storb
Fred Hutchinson Cancer Research Center, Seattle, Washington
Correspondence and reprint requests: Beverly Torok-Storb, PhD, Fred Hutchinson Cancer Research Center, 1100
Fairview Ave. N., D1-100, P.O. Box 19024, Seattle, WA 98109-1024 (e-mail: btorokst@fhcrc.org).
Received July 28, 2004; accepted September 1, 2004
ABSTRACT
A multivariate analysis of 121 dogs conditioned with 200, 100, or 50 cGy of total body irradiation (TBI)
followed by hematopoietic stem cell transplantation from matched littermates showed that TBI dose was the
only factor examined that was statistically significantly associated with the percentage of donor myeloid
engraftment in stable long-term chimeras (P  .008). To understand the direct effects of low-dose irradiation
on hematopoietic stem/progenitor cells, nonirradiated and irradiated human CD34 cells were evaluated for
competitive repopulating ability in nonobese diabetic/severe combined immunodeficiency beta2m/mice. As
expected, the results showed a radiation dose–dependent loss of competitive repopulating ability. Flow
cytometric analysis indicated that, within a viable cell gate, there was reduced expression of P-selectin
glycoprotein ligand-1 and L selectin on irradiated compared with nonirradiated CD34 cells; this suggests that
irradiated stem/progenitor cells may be compromised in their ability to home to or interact with the marrow
microenvironment. However, the CD34/P-selectin glycoprotein ligand-1 dim cells also showed activation of
caspase-3, indicating that they were destined to die. These results suggest that the TBI dose determines the
degree of myeloid engraftment by compromising the resident stem/progenitor cell compartment.
© 2004 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
The nonmyeloablative preparative regimen devel-
ped at the Fred Hutchinson Cancer Research Center
FHCRC) consists of ﬂudarabine and 200 cGy of total
ody irradiation (TBI) in combination with cyclospor-
ne (CSP) and mycophenolate mofetil (MMF) given
or immunosuppression after transplantation [1,2].
his approach relies on ensuing graft-versus-host
GVH) reactions to eradicate both the recipient’s ma-
ignant and normal hematopoietic cells, and the pre-
arative regimen is thought to immediately compro-
ise recipient T cells that would otherwise cause graft
ejection [3]. When rejection does occur, there is
sually prompt reconstitution by host hematopoietic
ells, suggesting that only minimal radiation-induced
amage was sustained by recipient stem/progenitor
ells. As might be expected, there is little acute toxicity
rom this conditioning regimen. However, even very b
26ow doses of ionizing irradiation have been associated
ith late toxicities such as secondary cancers [4],
hich are unacceptable toxicities for patients who
ndergo transplantation for nonmalignant diseases
uch as hemoglobinopathies and immune deﬁciency
yndromes. Therefore, it is desirable to replace the
BI in the conditioning regimen for these patients.
Preclinical studies in the dog leukocyte antigen
DLA)–identical bone marrow transplant model have
hown that uniform and sustained donor cell engraft-
ent is difﬁcult to achieve at TBI doses 200 cGy
espite intensiﬁcation of pharmacologic immunosup-
ression before, during, or after transplantation [5-7].
urthermore, the exceedingly small proportion of
ogs that did achieve stable donor engraftment at TBI
oses 200 cGy typically developed mixed chimer-
sm, with donor contributions to hematopoiesis well
elow 50%. We interpret these observations to sug-
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Radiation Dose and Myeloid Chimerism
Best that 200 cGy of TBI, if not directly lethal to stem
ells, may compromise them in such a way as to
rovide a competitive advantage to infused donor
tem cells and that this radiobiological effect is lost at
oses 100 cGy.
Here we report a retrospective analysis of the
egree and duration of chimerism in canine recipients
f stem cell transplants from DLA-identical litter-
ates. The data suggest that both the degree and sta-
ility of chimerism are associated with TBI dose and that
further reduction of the TBI dose 200 cGy may
equire additional strategies to compromise the func-
ion or reduce the number of recipient stem cells to
llow adequate donor cell engraftment.
ATERIALS AND METHODS
og Studies
Litters of Beagles, Harriers, and Walker hounds
ere either raised at the FHCRC (Seattle, WA) or
urchased from commercial kennels in the state of
ashington. They were observed at least 60 days
efore they entered the studies. All were immunized
or leptospirosis, hepatitis, distemper, and parvovirus.
esearch was performed according to the principles
utlined in the Guide for the Care and Use of Laboratory
nimals prepared by the National Academy of Sci-
nce, National Research Council. All research proto-
ols were approved by the Institutional Animal Care
nd Use Committee of the FHCRC. The kennels
ere certiﬁed by the American Association for the
ccreditation of Laboratory Animal Care.
One hundred twenty-one DLA-identical litter-
ate pairs that had undergone transplantation at the
HCRC on different protocols since 1997 were in-
luded in this analysis. DLA identity was conﬁrmed as
ublished previously [8-10]. Recipients were given
BI at doses of 200 cGy (26 dogs), 100 cGy (76 dogs),
nd 50 cGy (19 dogs) delivered from 2 opposing
obalt-60 sources [11] or a high-energy linear acceler-
tor (CLINAC4; Varian, Palo Alto, CA). Both sources
ere calibrated to deliver 7 cGy/min or 9.3 rads. The
ay of marrow grafting was designated as day 0. Fifty-
ight dogs received bone marrow alone, 42 dogs re-
eived bone marrow in combination with granulocyte
olony-stimulating factor–mobilized peripheral blood
ononuclear cells (G-PBMC), 13 dogs received
one marrow in combination with CD14-depleted
-PBMC, and 8 dogs received bone marrow in com-
ination with T cell–depleted G-PBMC. Posttrans-
lant immunosuppression consisted of CSP (15 mg/kg
wice daily orally on days 1 to 35; n  53); CSP in
ombination with MMF (10 mg/kg twice daily subcu-
aneously on days –1 to 27; n  23); CSP and rapa-
ycin (0.05 mg/kg daily subcutaneously on days 0 to
7; n  12); CSP, MMF, and rapamycin (n  5); or c
B&MTSP and MMF in combination with pretransplanta-
ion immunosuppression (n  28). The pretransplan-
ation immunosuppression consisted of methotrexate,
lt3 ligand, or cytotoxic T-lymphocyte antigen 4-
mmunoglobulin. The preparation of marrow and
-PBMC products has been described in detail pre-
iously [12].
Stable engraftment was deﬁned as sustained recov-
ries of granulocyte and platelet counts after the
ostirradiation nadir and by documentation of donor
ells in the peripheral blood. A polymerase chain re-
ction–based assay that detects polymorphic (CA)n
epeats was used to demonstrate the donor cell con-
ribution to the recipient’s hematopoiesis after trans-
lantation [13]. This technique detects 2.5% to 97.5%
ixtures of donor and host cells. Mixed hematopoietic
himerism was quantiﬁed by estimating the propor-
ion of donor-speciﬁc DNA among host DNA by
sing the storage phosphor imaging technique [14].
ecause immunologic rejection does not occur be-
ond 26 weeks after transplantation in this model,
eak chimerism was determined at an early (weeks
-12) and a late (after week 26) time point and was
orrelated with TBI dose.
uman G-PBMC–Derived CD34 Cells
Cryopreserved human CD34 cells were isolated
rom G-PBMC by magnetic bead separation [15]. The
ells were rapidly thawed and suspended to a ﬁnal
olume of 50 mL in phosphate-buffered saline (PBS)
ith 1% fetal calf serum (FCS). Cells were washed
wice in PBS with 1% FCS, resuspended in 2 mL of
BS with 1% FCS, and kept on ice until further
nalysis.
x Vivo Irradiation
Human CD34 cells were irradiated ex vivo with
high-energy linear accelerator (CLINAC4) at
cGy/min; irradiation doses ranged between 200 and
5 cGy. After irradiation, the cells were washed and
esuspended in Iscove modiﬁed Dulbecco medium
nd 10% FCS.
low Cytometric Analysis
Cells were irradiated as described previously. Un-
rradiated CD34 cells were used as a control. The
ells were cultured for 24 hours in Iscove medium
upplemented with 10% FCS, 10 ng/mL interleu-
in-3, and 10 ng/mL stem cell factor at 37°C under
5% air/5% CO2. The cells were then washed with
BS/10% FCS and stained with the following mono-
lonal antibodies (2 L of each antibody/20 L/106
ells) for 15 minutes at 4°C: anti-CD49a phyco-
rythrin (PE), clone SR84 (PharMingen, San Diego
A); anti-CD49b ﬂuorescein isothiocyanate (FITC),
lone AK7 (PharMingen); anti-CD49c PE, clone
827
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83II.1 (PharMingen); anti-CD49d FITC, clone
P2/1 (AMAC, Westbrook, ME); anti-CD49f FITC,
lone GoH3 (PharMingen); anti-CD11a FITC, clone
5.3 (AMAC); anti-CD31 FITC, clone 5.6E (AMAC);
nti-CD44 FITC, clone J.173 (Immunotech, Mar-
eille, France); anti-CD54 FITC, clone 84H10 (Im-
unotech); anti-CD62L FITC, clone SK11 (Phar-
ingen); anti-CD62P FITC, clone AK4 (PharMin-
en); anti-CD62E PE, clone 68-5H11 (PharMingen);
nti-CXCR-4 FITC, clone 12P5 (R&D Systems,
inneapolis, MN); and anti-CD162 (P-selectin gly-
oprotein ligand-1; PSGL-1), clone KPL-1 (PharM-
ngen). After washing with PBS/5% bovine serum
lbumin, cells were resuspended and kept on ice until
ow cytometric analysis. The ﬂuorescence intensity
as measured with a FACScan (Becton Dickinson,
an Jose, CA). Nonviable cells were excluded by pro-
idium iodine staining performed immediately before
ow cytometric analysis.
poptosis Assay
A caspase-3 detection kit (FITC-DEVD-FMK;
ncogene Research Products, San Diego, CA) was
sed to identify cells entering the apoptotic pathway.
ells were irradiated and incubated for 24 hours as
escribed previously. The cells were then stained with
ITC-DEVD-FMK (1 L/1  106 cells) for 30 min-
tes at 4°C. After washing with PBS/5% bovine serum
lbumin, cells were resuspended and kept on ice until
ow cytometric analysis. The ﬂuorescence intensity
as measured with a FACScan (Becton Dickinson).
onviable cells were excluded by propidium iodine
taining immediately before ﬂow cytometric analysis.
ompetitive Nonobese Diabetic/Severe Combined
mmunodeficiency Repopulating Ability
Nonobese diabetic/severe combined immunodeﬁ-
iency (NOD/SCID) beta2m/ mice were bred and
aintained by the NOD/SCID core resource at FH-
RC (supported by P30 DK56465). The breeders (stock
o. 002570, strain NOD.Cg-Prkdcscid2mtmlUnc/J) were
urchased from Jackson Laboratories (Bar Harbor, ME).
he mice were kept in microisolator cages and fed with
cidiﬁed H2O and irradiated food. After 7 to 10 weeks,
ice were used for the competitive repopulation assay.
Brieﬂy, 1.1  106 CD34 cells from each of 2
nrelated healthy human donors were injected intra-
enously into sublethally irradiated (350 cGy; CLI-
AC4) recipient mice. In the control group, both cell
opulations were unirradiated. In the experimental
roup, one cell population was irradiated with 50, 100,
r 200 cGy just before injection. After 3, 7, and
0 weeks, human cell engraftment in bone marrow
as estimated by ﬂow cytometry as the percentage of
uman CD45 cells. The relative contribution of each
onor to the human hematopoiesis of recipient mice f
28as determined by ﬂuorescence variable number tan-
em repeats (VNTR) analysis.
NTR Analysis of Human Cells
VNTR analysis is provided as a core service by
30 DK56465. Brieﬂy, DNA was puriﬁed with the
IAamp DNA Mini Kit (Qiagen, Valencia, CA).
he ratio of the 2 donor cell populations in mouse
one marrow was quantitated by ﬂuorescent VNTR
nalysis, as described by Scharf et al. [16], with the
ollowing modiﬁcations. Polymerase chain reactions
20-L volume) contained 50 to 200 ng of DNA,
.4 L of Advantage II polymerase mix (Clontech,
alo Alto, CA), 1 Advantage II buffer, de-
xynucleoside triphosphates at 200 M each, and
uman primers at 50 nM each. Primers used were
=-(6-FAM)-CCCTAGTGGATGATAAGAATAATC
nd 5=-GGACAGATGATAAATACATAGGATG-
ATGG, corresponding to the HUMVWA locus
17], and 5=-6-(FAM)-ACATCTCCCCTACCGCTA-
A and 5=-AATCTGGGCGACAAGAGTGA, corre-
ponding to the SE33 locus [18]. Polymerase chain
eaction conditions included a hold at 94°C for 5 min,
0 or 33 cycles (for HUMVWA or SE33, respectively)
f 10 seconds at 94°C, 30 seconds at 57°C, and 60
econds at 68°C, followed by a hold at 68°C at 10
inutes. In cases in which DNA was limiting, ampli-
cation was performed for 40 cycles. Products were
eparated and documented by capillary electrophore-
is on an ABI Prism 310 genetic analyzer and quanti-
ated with Gene Scan 3.1 Software (Applied Biosys-
ems, Foster City, CA).
tatistical Analysis
Univariate and multivariate analysis of variance
as used to assess the inﬂuence of TBI dose, stem cell
ource, and immunosuppression on the degree and
uration of chimerism.
ESULTS
ssociation between TBI Dose and Degree or
uration of Donor Engraftment in the
LA-Identical Dog Model
Engraftment was analyzed among 121 pairs of
atched littermates enrolled in different low-dose
BI transplantation studies at the FHCRC since
997. Percentages of donor granulocytes during weeks
to 12 were available in all dogs. Chimerism data after
eek 26 were available in 112 dogs (92.5%). Four
ogs in the 200 cGy group received recipient lym-
hocyte infusions before week 26 for conversion into
ull host chimerism, and 5 dogs in the 100 cGy group
ere killed before week 26: these dogs were excludedrom the analysis for late engraftment. Thirty-nine
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Radiation Dose and Myeloid Chimerism
Bogs (34.8%) achieved stable long-term engraftment
26 weeks).
The degree of donor cell engraftment is accurately
eﬂected in the percentage of donor granulocytes in
he peripheral blood [19], which was therefore used as
surrogate marker to estimate both the degree of
himerism and the proportion of dogs with late (sta-
le) chimerism. Table 1 shows the univariate and
ultivariate analyses of the effects of TBI, stem cell
ource, and type of immunosuppression on the degree
f donor chimerism. In the univariate analysis, both
he TBI dose and the type of immunosuppression
igniﬁcantly inﬂuenced the degree of chimerism at the
arly and late time points. In the multivariate analysis,
he TBI dose and stem cell source, but not the type of
mmunosuppression, were associated with the degree
f donor chimerism at the early time point; only the
BI dose had a statistically signiﬁcant effect on the
egree of chimerism at the late time point. Table 2
hows that in a multivariate analysis, TBI dose and
tem cell source were signiﬁcantly associated with the
roportion of dogs that achieved long-term stable
ngraftment.
ow-Dose Irradiation of CD34 Cells Reduces
heir Competitive Repopulating Ability
The results obtained in the canine transplantation
odel showed that the radiation dose was statistically
igniﬁcantly associated with the degree of donor my-
loid chimerism. To determine whether this effect is
ediated by directly compromising the host stem/
rogenitor compartment, thereby conferring a com-
able 1. Univariate and Multivariate Analyses of the Degree of Chime
mmunosuppression in DLA-Identical Littermates
Variable
Early Chim
n Me
BI dose (cGy)
50 19 24
100 76 34
200 26 70
tem cell source
BM 58 42
BM  G-PBMC 42 38
BM  G-PBMC (CD14 depleted) 13 39
BM  G-PBMC (CD3 depleted) 8 43
ostgrafting immunosuppression
CSP 53 45
CSP, MMF 23 40
CSP, rapamycin 12 53
CSP, MMF, rapamycin 5 36
CSP, MMF in combination with
pretransplantation
immunosuppression 28 27
SP indicates cyclosporine; MMF, mycophenolate mofetil; BM, b
peripheral blood mononuclear cell; TBI, total body irradiation;
Multivariate P value reﬂecting adjustment for other factors.etitive advantage to donor cells, we competed irra- *
B&MTiated CD34 cells with nonirradiated cells in a SCID
epopulating assay. CD34 cells from 2 unrelated
ealthy human donors were injected intravenously
nto sublethally irradiated NOD/SCID beta2m/
ccording to TBI Dose, Stem Cell Source, and Postgrafting
(1-12 wk) Late Chimerism (>26 wk)
P Value n Mean P Value
<.0001 4 24.0 .04
19 52.4
<.0001* 16 65.5 .008*
13 48.2
.89 19 57.7 .68
.01* 7 59.3 .54*
0 —
21 65.4
8 32.9
.06 5 59.8 .04
0 —
.61* 5 40.8 .19*
rrow; G-PBMC, granulocyte colony-stimulating factor–mobilized
dog leukocyte antigen.
able 2. Multivariate Analyses of Duration of Chimerism According
o TBI Dose, Stem Cell Source, and Postgrafting Immunosuppression in
LA-Identical Littermates
Variable
Stable Engraftment
(>26 wk)
n
Mean
(%)
P
Value*
BI dose (cGy)
50 4/19 21.0
100 19/71 26.7 .0001
200 16/22 72.7
tem cell source
BM 13/45 28.8
BM  G-PBMC 19/50 38.0
BM  G-PBMC
(CD14 depleted) 7/11 63.6 .004
BM  G-PBMC
(CD3 depleted) 0/6 0
ostgrafting immunosuppression
CSP 21/49 42.8
CSP, MMF 8/19 42.1
CSP, rapamycin 5/12 41.6
CSP, MMF, rapamycin 0/5 0 .69
CSP, MMF in combination with
pretransplantation
immunosuppression 5/27 18.5
SP indicates cyclosporine; MMF, mycophenolate mofetil; BM,
bone marrow; G-PBMC, granulocyte colony-stimulating fac-
tor–mobilized peripheral blood mononuclear cell; TBI, total
body irradiation; DLA, dog leukocyte antigen.rism A
erism
an
.4
.6
.9
.7
.9
.4
.1
.2
.5
.9
.8
.9
one ma
DLA,Multivariate P value reﬂecting adjustment for other factors.
829
m
d
e
s
t
u
e
n
d
T
r
2
5
i
.
w
r
L
D
a
1
o
w
(
p
2
l
.
s
e
c
C
C
p
i
i
c
a
r
g
o
l
D
e
l
w
m
i
t
p
b
i
m
d
w
r
N
t
c
t
d
u
l
d
t
t
p
m
h
i
p
n
T
F
F
C
N
c
o
d
V
C. Kahl et al.
8ice. By using VNTR analysis, it was possible to
etect the proportion of human cells contributed by
ach donor. The results from these experiments are
ummarized in Figure 1 and Table 3, which show that
he 2 sources of human CD34 cells, when both were
nirradiated, contributed almost equally to human
ngraftment in recipient mice (43% versus 57%;
 21). However, once irradiated, the contribution
ecreased in a dose-dependent manner (Figure 1).
he observed competitive repopulating ability of ir-
adiated cells was reduced by approximately 74% after
00 cGy, by 24% after 100 cGy, and by 6% after
0 cGy (Table 3). The reduction in engraftment abil-
ty after 200 cGy was statistically signiﬁcant (P 
0001), whereas the reductions after 100 and 50 cGy
ere not statistically signiﬁcant (P  .26 and P  .61,
espectively).
ow-Dose Irradiation of CD34 Cells Leads to a
ecreased Expression of PSGL-1 and L Selectin
nd Increased Activation of Caspase-3
CD34 cells were irradiated ex vivo with 25, 50,
00, and 200 cGy; incubated overnight in the presence
f interleukin-3 and stem cell factor; and then stained
ith monoclonal antibodies for adhesion molecules
described previously). An unirradiated CD34 cell
opulation was used as a control. As shown in Figure
C and D, 200 cGy of irradiation led to a signiﬁcant
oss of PSGL-1 expression on the cell surface (P 
002) which was radiation dose dependent (data not
hown). There was a similar reduction in the surface
xpression of L selectin (P  .006). No changes in the
igure 1. A, Contribution to human hematopoiesis by irradiated
D34 cells in competition with nonirradiated CD34 cells in the
OD/SCID beta2m/ mice (0 cGy, n  21; 50 cGy, n  6; 100
Gy, n  9; 200 cGy, n  11). Three experiments were performed
ver 9 months. The percentage contributed by the 2 different
onors to mouse bone marrow after 10 weeks was determined by
NTR (bars represent SE).ell-surface expression of CD49a, CD49b, CD49c, (
30D49d, CD49f, anti-CD11a, CD31, CD44, CD54,
D62E, or CXCR4 were observed over this time
eriod.
Additional ﬂow cytometric analysis (Figure 2E-G)
ndicated a statistically signiﬁcant increase (P  .009)
n the proportion of CD34 cells with activated
aspase-3 after 200 cGy. Dual analysis for caspase-3
nd PSGL-1 indicated that the CD34 cells that had
educed expression of PSGL-1 had also entered pro-
rammed cell death, as evidenced by their activation
f caspase-3. Similar results were obtained for L se-
ectin (data not shown).
ISCUSSION
Our retrospective analysis of dogs given nonmy-
loablative stem cell transplants from DLA-identical
ittermates showed that TBI dose and stem cell source
ere signiﬁcantly associated with stability of engraft-
ent. However, TBI dose was the only factor exam-
ned in a multivariate analysis that was associated with
he degree of donor chimerism. This observation
rompted us to investigate whether, in addition to
eing immunosuppressive, low-dose TBI might facil-
tate engraftment by compromising the recipient’s he-
atopoietic stem/progenitor cell compartment.
To address this issue, the direct effect of radiation
ose on the repopulating ability of hematopoietic cells
as investigated by competing irradiated with nonir-
adiated human CD34 cells in sublethally irradiated
OD/SCID beta2m/ mice. In these experiments,
he 2 sources of CD34 cells, when not irradiated,
ontributed equally to the human hematopoiesis de-
ected in recipient mice. After 200 cGy given at a low
ose rate of 7 cGy/min, the irradiated source contrib-
ted 74% less than expected, and it contributed 24%
ess after 100 cGy and 6% less after 50 cGy. These
ata demonstrated a radiation dose–dependent reduc-
ion in NOD/SCID repopulating ability. Whether
his represented radiation-induced cell killing or com-
romised function—ie, failure of cells to home to the
icroenvironment—was not addressed by this assay.
Additional pilot studies had suggested that within
ours of irradiation, the number of mononuclear cells
n the blood increased 3- to 5-fold and that the pro-
ortion of CD34 cells increased 1.5- to 3-fold (data
ot shown). We speculated that this might be due to
able 3. Calculated Percentage Reduction in Repopulating Ability as a
unction of Radiation Dose
Radiation dose
(cGY)
%
observed
%
expected
% reduction in
competitive capacity
50 40.6 43.4 6.5
100 32.8 43.4 24.4
200 11.1 43.4 74.4% expected  % observed)/% expected  100.
r
p
s
i
e
p
a
W
t
a
F
t
o adiated
Radiation Dose and Myeloid Chimerism
Badiation-induced changes in adhesion molecule ex-
ression. To test this hypothesis, we examined expres-
ion levels of various adhesion molecules hours after
rradiation.
Flow cytometric analysis of viable CD34 cells
igure 2. The effect of 200 cGy on PSGL-1 expression and apopt
his analysis is a representative experiment, which was repeated 5 ti
f small cells in the irradiated group (B) compared with the nonirrxposed to 200 cGy indicated that a signiﬁcant pro- p
B&MTortion of cells had reduced expression of L selectin
nd PSGL-1 compared with nonirradiated cells.
hether these changes could contribute to mobiliza-
ion in vivo is unknown. Some reports have described
role for PSGL-1 or L selectin in hematopoietic
viable human CD34 cells (propidium iodine negative). Shown in
he forward- and side-scatter properties show an increased number
group.osis in
mes. Trogenitor cell homing [20-23]. In addition, P-selec-
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8in and L-selectin knockout mice have been shown to
ave defective progenitor cell rolling along endothe-
ial surfaces and impaired progenitor cell homing to
he bone marrow. Given that stem cells are postulated
o be constantly recirculating between the marrow and
lood, TBI-induced downregulation of adhesion re-
eptors on recipient hematopoietic stem cells might
e associated with their retention in the blood. We
urther speculated that mobilizing recipient stem cells
ut of the marrow microenvironment and preventing
heir efﬁcient homing might serve to provide empty
iches for donor stem cells. This speculation was
rompted by a report by Abkowitz et al. [24], who
howed in a parabiotic rodent model that engraftment
f partner stem cells was augmented if the animals
ere treated with a mobilizing cytokine. Mobilization
ollowed by impaired homing of recipient stem cells
ould result in a competitive advantage for trans-
lanted donor stem cells, given their unaltered reper-
oire of adhesion molecules.
Further analysis of ex vivo–irradiated CD34 cells
evealed that, although all cells analyzed appeared
iable, many of the cells with decreased expression of
electins showed activation of caspase-3 and were
herefore destined to die. From these observations, we
ypothesize that CD34 cells lose their adhesion mol-
cule expression as a consequence of entering the
poptotic pathway or that cells lose their adhesion
olecule expression, fail to home, and, as a conse-
uence, enter the apoptotic pathway. Either way,
D34 cells are released from their niches in the mar-
ow. Whether their release from the marrow is sufﬁ-
ient to make space for donor cells or whether their
ltimate removal through apoptosis is required is not
ddressed by these studies. However, these ﬁndings do
how that low doses of irradiation have the potential
o disrupt communication between CD34 cells and
heir stromal niches and to kill resident CD34 cells.
his may confer a functional or numeric advantage to
onor stem cells over recipient stem cells.
The role of stem cell competition in engraftment
as been well described. Stewart et al. [25] showed
hat long-term chimerism could be established after
ransplantation of megadoses (2  108 cells) of donor
arrow into nonmyeloablated recipients. The authors
oncluded that creation of marrow space was not a
equirement for successful engraftment. However, it
eems reasonable to conclude that the megadoses pro-
ided a numeric advantage for donor cells to compete
or niches that become available through normal traf-
cking. However, the high number of marrow cells
ransplanted in this mouse model makes it difﬁcult to
ranslate this experience into large animals or human
atients. Instead of providing very high numbers of
onor cells, other investigators have attempted to
hange the donor/recipient balance by removing re-
ipient stem cells by using myeloablative TBI or che-
32otherapy. In nonmyeloablative models, GVH reac-
ions are postulated to reduce the number of recipient
tem cells. However, in our matched-littermate canine
odel, there was little to no GVH disease, presum-
bly because of the young age of the recipients. The
bsence of clinically signiﬁcant GVH disease may
ave made it easier to detect the effect of TBI dose on
onor engraftment.
In conclusion, our ﬁndings suggest that low-dose
BI determines the degree of donor cell engraftment
y compromising host stem cells and, consequently,
roviding a competitive advantage to donor cells. This
ffect is in addition to the well-documented immuno-
uppressive TBI effects that prevent rejection and
hereby permit engraftment. Whether the omission of
onizing irradiation from nonmyeloablative prepara-
ive regimens is a realistic goal depends on our ability
o identify relatively nontoxic agents that target the
ost stem cell compartment in such a way as to pro-
ide the competitive advantage needed by the incom-
ng donor stem cells.
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